A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors

Conditions

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

To evaluate the safety of GEN1042 in patients with malignant solid tumors.

Find out more about who can participate in this trial

Trial with
Genmab, Inc.
Start Date
10/07/2020
End Date
11/30/2020

For more information about this study, contact:

Ingrid Palma

203.785.6431
ingrid.palma@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Patricia LoRusso, DO
Professor of Medicine (Medical Oncology); Professor of Medicine; Associate Cancer Center Director, Experimental Therapeutics

Sub-Investigators

Joseph Kim, MD
Joseph Paul Eder, MD
Mandy DeMerchant
Michael Cecchini, MD
Michael Lachowicz
Navid Hafez, MD, MPH

Last Updated
10/09/2020
Study HIC
#2000027214

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information